Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients
The aim of our study was to find a therapeutic range for the serum concentration of zuclopenthixol (S-Zu) in chronic schizophrenic patients. S-Zu was measured in 17 patients and dosage reduction was suggested by the laboratory if S-Zu exceeded 15 nmol/L. The clinical symptoms and side effects were e...
Gespeichert in:
| Veröffentlicht in: | Therapeutic drug monitoring 1994-12, Vol.16 (6), p.541-547 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 547 |
|---|---|
| container_issue | 6 |
| container_start_page | 541 |
| container_title | Therapeutic drug monitoring |
| container_volume | 16 |
| creator | KJØLBYE, M THOMSEN, K ROGNE, T REHFELT, E OLESEN, O. V |
| description | The aim of our study was to find a therapeutic range for the serum concentration of zuclopenthixol (S-Zu) in chronic schizophrenic patients. S-Zu was measured in 17 patients and dosage reduction was suggested by the laboratory if S-Zu exceeded 15 nmol/L. The clinical symptoms and side effects were evaluated blindly using the Brief Psychiatric Rating Scale (BPRS) and the UKU rating scale, respectively. S-Zu and ratings were repeated 6, 12, and 24 weeks after the final dosage adjustments. In 7 of 10 patients with S-Zu > 15 nmol/L the dosage was reduced by 20-67%. After dosage reduction the S-Zu was below 15 nmol/L in 10 of the 17 patients. The mean BPRS score and the side effects, evaluated by the UKU scale, were reduced in patients in whom the dosage was reduced. It is suggested that S-Zu in the range 5-15 nmol/L may serve as a preliminary therapeutic range for S-Zu. |
| doi_str_mv | 10.1097/00007691-199412000-00002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77757040</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77757040</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-7b135a9598d5df54cdd6fafe28453c3a305cc1a9c424af7fb4b22ac7e3daab2b3</originalsourceid><addsrcrecordid>eNo9kEtLxDAQx4Mo6_r4CEIO4q2aNEnTHEV8geBBPdfpNLGVblOTFtRPb1bXncsw_0cCP0IoZ-ecGX3B0ujC8IwbI3mermwt5TtkyZUoMlEYuUuWjBcik0IV--QgxnfGuCwZW5CFLnWZ6kvy-mQhYEudDxTo1NoAo52nDmmA4c3-6tGGeUW_Z-z9aIep7T59T9EPmI4AU-eHSLuBRmy7bz-2wQ6pPiYj-fGI7Dnooz3e7EPycnP9fHWXPTze3l9dPmQohJkyXXOhwChTNqpxSmLTFA6czUupBAoQTCFyMChzCU67WtZ5DqitaADqvBaH5Ozv3TH4j9nGqVp1EW3fw2D9HCuttdJMshQs_4IYfIzBumoM3QrCV8VZtYZb_cOttnB_pTxVTzZ_zPXKNtvihmbyTzc-RITeJYTYxW1MCM05Y-IHInqEig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77757040</pqid></control><display><type>article</type><title>Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>KJØLBYE, M ; THOMSEN, K ; ROGNE, T ; REHFELT, E ; OLESEN, O. V</creator><creatorcontrib>KJØLBYE, M ; THOMSEN, K ; ROGNE, T ; REHFELT, E ; OLESEN, O. V</creatorcontrib><description>The aim of our study was to find a therapeutic range for the serum concentration of zuclopenthixol (S-Zu) in chronic schizophrenic patients. S-Zu was measured in 17 patients and dosage reduction was suggested by the laboratory if S-Zu exceeded 15 nmol/L. The clinical symptoms and side effects were evaluated blindly using the Brief Psychiatric Rating Scale (BPRS) and the UKU rating scale, respectively. S-Zu and ratings were repeated 6, 12, and 24 weeks after the final dosage adjustments. In 7 of 10 patients with S-Zu > 15 nmol/L the dosage was reduced by 20-67%. After dosage reduction the S-Zu was below 15 nmol/L in 10 of the 17 patients. The mean BPRS score and the side effects, evaluated by the UKU scale, were reduced in patients in whom the dosage was reduced. It is suggested that S-Zu in the range 5-15 nmol/L may serve as a preliminary therapeutic range for S-Zu.</description><identifier>ISSN: 0163-4356</identifier><identifier>EISSN: 1536-3694</identifier><identifier>DOI: 10.1097/00007691-199412000-00002</identifier><identifier>PMID: 7878691</identifier><identifier>CODEN: TDMODV</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Chronic Disease ; Clopenthixol - administration & dosage ; Clopenthixol - blood ; Clopenthixol - therapeutic use ; Denmark ; Drug Monitoring ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Pharmacology. Drug treatments ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Schizophrenia - blood ; Schizophrenia - drug therapy ; Time Factors</subject><ispartof>Therapeutic drug monitoring, 1994-12, Vol.16 (6), p.541-547</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-7b135a9598d5df54cdd6fafe28453c3a305cc1a9c424af7fb4b22ac7e3daab2b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3371100$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7878691$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KJØLBYE, M</creatorcontrib><creatorcontrib>THOMSEN, K</creatorcontrib><creatorcontrib>ROGNE, T</creatorcontrib><creatorcontrib>REHFELT, E</creatorcontrib><creatorcontrib>OLESEN, O. V</creatorcontrib><title>Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients</title><title>Therapeutic drug monitoring</title><addtitle>Ther Drug Monit</addtitle><description>The aim of our study was to find a therapeutic range for the serum concentration of zuclopenthixol (S-Zu) in chronic schizophrenic patients. S-Zu was measured in 17 patients and dosage reduction was suggested by the laboratory if S-Zu exceeded 15 nmol/L. The clinical symptoms and side effects were evaluated blindly using the Brief Psychiatric Rating Scale (BPRS) and the UKU rating scale, respectively. S-Zu and ratings were repeated 6, 12, and 24 weeks after the final dosage adjustments. In 7 of 10 patients with S-Zu > 15 nmol/L the dosage was reduced by 20-67%. After dosage reduction the S-Zu was below 15 nmol/L in 10 of the 17 patients. The mean BPRS score and the side effects, evaluated by the UKU scale, were reduced in patients in whom the dosage was reduced. It is suggested that S-Zu in the range 5-15 nmol/L may serve as a preliminary therapeutic range for S-Zu.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Clopenthixol - administration & dosage</subject><subject>Clopenthixol - blood</subject><subject>Clopenthixol - therapeutic use</subject><subject>Denmark</subject><subject>Drug Monitoring</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Schizophrenia - blood</subject><subject>Schizophrenia - drug therapy</subject><subject>Time Factors</subject><issn>0163-4356</issn><issn>1536-3694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLxDAQx4Mo6_r4CEIO4q2aNEnTHEV8geBBPdfpNLGVblOTFtRPb1bXncsw_0cCP0IoZ-ecGX3B0ujC8IwbI3mermwt5TtkyZUoMlEYuUuWjBcik0IV--QgxnfGuCwZW5CFLnWZ6kvy-mQhYEudDxTo1NoAo52nDmmA4c3-6tGGeUW_Z-z9aIep7T59T9EPmI4AU-eHSLuBRmy7bz-2wQ6pPiYj-fGI7Dnooz3e7EPycnP9fHWXPTze3l9dPmQohJkyXXOhwChTNqpxSmLTFA6czUupBAoQTCFyMChzCU67WtZ5DqitaADqvBaH5Ozv3TH4j9nGqVp1EW3fw2D9HCuttdJMshQs_4IYfIzBumoM3QrCV8VZtYZb_cOttnB_pTxVTzZ_zPXKNtvihmbyTzc-RITeJYTYxW1MCM05Y-IHInqEig</recordid><startdate>19941201</startdate><enddate>19941201</enddate><creator>KJØLBYE, M</creator><creator>THOMSEN, K</creator><creator>ROGNE, T</creator><creator>REHFELT, E</creator><creator>OLESEN, O. V</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19941201</creationdate><title>Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients</title><author>KJØLBYE, M ; THOMSEN, K ; ROGNE, T ; REHFELT, E ; OLESEN, O. V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-7b135a9598d5df54cdd6fafe28453c3a305cc1a9c424af7fb4b22ac7e3daab2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Clopenthixol - administration & dosage</topic><topic>Clopenthixol - blood</topic><topic>Clopenthixol - therapeutic use</topic><topic>Denmark</topic><topic>Drug Monitoring</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Schizophrenia - blood</topic><topic>Schizophrenia - drug therapy</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KJØLBYE, M</creatorcontrib><creatorcontrib>THOMSEN, K</creatorcontrib><creatorcontrib>ROGNE, T</creatorcontrib><creatorcontrib>REHFELT, E</creatorcontrib><creatorcontrib>OLESEN, O. V</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Therapeutic drug monitoring</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KJØLBYE, M</au><au>THOMSEN, K</au><au>ROGNE, T</au><au>REHFELT, E</au><au>OLESEN, O. V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients</atitle><jtitle>Therapeutic drug monitoring</jtitle><addtitle>Ther Drug Monit</addtitle><date>1994-12-01</date><risdate>1994</risdate><volume>16</volume><issue>6</issue><spage>541</spage><epage>547</epage><pages>541-547</pages><issn>0163-4356</issn><eissn>1536-3694</eissn><coden>TDMODV</coden><abstract>The aim of our study was to find a therapeutic range for the serum concentration of zuclopenthixol (S-Zu) in chronic schizophrenic patients. S-Zu was measured in 17 patients and dosage reduction was suggested by the laboratory if S-Zu exceeded 15 nmol/L. The clinical symptoms and side effects were evaluated blindly using the Brief Psychiatric Rating Scale (BPRS) and the UKU rating scale, respectively. S-Zu and ratings were repeated 6, 12, and 24 weeks after the final dosage adjustments. In 7 of 10 patients with S-Zu > 15 nmol/L the dosage was reduced by 20-67%. After dosage reduction the S-Zu was below 15 nmol/L in 10 of the 17 patients. The mean BPRS score and the side effects, evaluated by the UKU scale, were reduced in patients in whom the dosage was reduced. It is suggested that S-Zu in the range 5-15 nmol/L may serve as a preliminary therapeutic range for S-Zu.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>7878691</pmid><doi>10.1097/00007691-199412000-00002</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-4356 |
| ispartof | Therapeutic drug monitoring, 1994-12, Vol.16 (6), p.541-547 |
| issn | 0163-4356 1536-3694 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77757040 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Aged Biological and medical sciences Chronic Disease Clopenthixol - administration & dosage Clopenthixol - blood Clopenthixol - therapeutic use Denmark Drug Monitoring Female Humans Male Medical sciences Middle Aged Neuropharmacology Pharmacology. Drug treatments Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Schizophrenia - blood Schizophrenia - drug therapy Time Factors |
| title | Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T00%3A44%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Search%20for%20a%20therapeutic%20range%20for%20serum%20zuclopenthixol%20concentrations%20in%20schizophrenic%20patients&rft.jtitle=Therapeutic%20drug%20monitoring&rft.au=KJ%C3%98LBYE,%20M&rft.date=1994-12-01&rft.volume=16&rft.issue=6&rft.spage=541&rft.epage=547&rft.pages=541-547&rft.issn=0163-4356&rft.eissn=1536-3694&rft.coden=TDMODV&rft_id=info:doi/10.1097/00007691-199412000-00002&rft_dat=%3Cproquest_cross%3E77757040%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77757040&rft_id=info:pmid/7878691&rfr_iscdi=true |